Posts by: Catarina Silva

The U.S. Food and Drug Administration has granted orphan drug status to Ryplazim, an idiopathic pulmonary fibrosis therapy that Prometic Life Sciences is developing. It’s the second time the FDA has designated a Prometic IPF ... Read more

December 19, 2017December 19, 2017

Pharmaxis, Synairgen Update Partnership to Advance Potential IPF Treatment in Clinical Trial

Idiopathic Pulmonary Fibrosis, News

Pharmaxis and Synairgen have revised their Lysyl Oxidase type 2 enzyme (LOXL2) program collaboration agreement, after obtaining positive results in preclinical studies and launching a Phase 1 clinical trial. Strong evidence suggests that ... Read more

November 30, 2017November 30, 2017

Skin Disease Atopic Dermatitis and Susceptibility to Allergies Increase Risk of Asthma, Study Finds

Asthma, News

Year-old infants who have a skin disease known as atopic dermatitis, and who are prone to allergies, are seven times more likely to develop asthma., a Canadian study finds. They ... Read more